The divestment of the business to Lone Star Funds enables Lonza’s transformation to become a pure-play contract development and manufacturing organization.
The investment will expand production, warehousing, and quality capabilities at the company’s Hengoed facility to strengthen medicine supply across the UK and Europe.
The CDMO expanded GMP analytical capabilities, including in vitro bioequivalence testing, to support early-stage development of inhaled and nasal therapies.
